{"filings":[{"id":678156,"accession_number":"0001104659-26-066623","cik":1130598,"company_name":"Traws Pharma, Inc.","ticker":"TRAW","form_type":"8-K","filed_at":"2026-05-27T12:50:46+00:00","items":["7.01","9.01"],"status":"ready","headline":"Traws Pharma announces antiviral program targeting Hantavirus and Ebola outbreaks","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Novel dual-strike combination agent exploits host nucleotide depletion and forced incorporation to halt viral replication.","Non-clinical development advancing in BSL-3/4 labs; plans to engage CDC, NAFDAC, and AMA for fast-track development.","Company scaling chemical manufacturing to enable immediate supply and potential stockpiling for health agencies.","Former CDC head Dr. Robert Redfield appointed CMO; CEO Iain Dukes highlights rapid response capabilities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":23180524.518987343,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":669957,"accession_number":"0001104659-26-066345","cik":1130598,"company_name":"Traws Pharma, Inc.","ticker":"TRAW","form_type":"8-K","filed_at":"2026-05-26T21:09:58+00:00","items":["8.01","9.01"],"status":"ready","headline":"Traws Pharma updates ATM offering to sell up to $3.1M in common stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amended ATM agreement with Citizens JMP Securities for up to $3,128,399 in common stock sales.","Shares sold under existing shelf registration (333-273081) via May 22, 2026 prospectus supplement.","Previous ATM capacity was $50M; new amount reflects current baby shelf limitation.","Legal opinion from Snell & Wilmer L.L.P. filed as Exhibit 5.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":23180524.518987343,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":452277,"accession_number":"0001104659-26-061771","cik":1130598,"company_name":"Traws Pharma, Inc.","ticker":"TRAW","form_type":"8-K","filed_at":"2026-05-15T11:05:36+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Traws Pharma Q1 net loss $7.1M; secures up to $60M PIPE financing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $7.1M ($0.53/share) vs net income of $21.5M in Q1 2025; revenue $0.","R&D expense $4.9M (up 96% YoY) on antiviral trial milestones; cash $3.1M at March 31.","Up to $60M private placement closed April 15 with $10M upfront, expected to fund ops into Q1 2027.","TXM influenza prophylaxis advancing to human challenge trial in Q2 2026; FDA clinical hold unresolved.","New hantavirus program initiated; no approved treatments exist for this disease."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":23180524.518987343,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91479,"accession_number":"0001104659-26-043781","cik":1130598,"company_name":"Traws Pharma, Inc.","ticker":"TRAW","form_type":"8-K","filed_at":"2026-04-15T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Traws Pharma FY2025 net income $9.2M (vs loss $166.5M); $60M PIPE with $10M upfront funds into Q1 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2025 net income $9.2M ($0.83 basic EPS) vs net loss $166.5M ($35.21 loss/share) in FY2024; revenue $2.8M (up from $0.2M).","Cash and equivalents $3.8M at Dec 31, 2025; PIPE up to $60M with $10M upfront to fund operations into Q1 2027.","TXM (influenza) Phase 1 bridging study ongoing; expects MHRA approval for human challenge trial in Q2 2026; FDA clinical hold unresolved.","Ratutrelvir (COVID) Phase 2a topline: faster symptom resolution in PAXLOVID-ineligible patients (HR 1.31, p=0.018); fewer adverse events vs comparator.","CEO Iain Dukes and CFO Charles Parker confirmed Oct 2025; John Leaman appointed independent director."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":23180524.518987343,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91478,"accession_number":"0001104659-26-043497","cik":1130598,"company_name":"Traws Pharma, Inc.","ticker":"TRAW","form_type":"8-K","filed_at":"2026-04-15T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Traws Pharma announces $10M PIPE (up to $60M with warrants) to fund UK flu challenge trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront gross proceeds of $10M from sale of ~5.98M shares at $1.6730/share; warrants could add $50M.","Proceeds to advance influenza program tivoxavir marboxil through Phase 2a human challenge trial in UK.","Warrant tranches: Series A ($10M upon MHRA approval), Series B ($10M post-data + shareholder OK), Series C ($30M, 3-year term).","Lead investor Sirenia Capital Management; Cantor Fitzgerald lead placement agent; closing expected April 16, 2026.","Company to file resale registration statement within 30 days of closing; shareholder meeting required for Series B/C warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":23180524.518987343,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101576,"accession_number":"0001104659-26-017298","cik":1130598,"company_name":"Traws Pharma, Inc.","ticker":"TRAW","form_type":"8-K","filed_at":"2026-02-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Traws Pharma: ratutrelvir Phase 2 shows fewer AEs, faster symptom resolution; FDA hold on tivoxavir IND","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Ratutrelvir Phase 2: 10% vs 23.3% adverse events, faster symptom resolution (HR 1.31, p=0.018), no viral rebound vs PAXLOVID.","Ratutrelvir showed benefit in PAXLOVID-ineligible patients, addressing unmet need in high-risk COVID-19 population.","Tivoxavir marboxil tablet formulation showed 30% increased pre-clinical exposure, modeled 28-day monthly prophylaxis.","FDA placed US IND for tivoxavir marboxil on clinical hold due to mutagenicity concerns; formal communication by March 16, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":23180524.518987343,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101575,"accession_number":"0001104659-26-006460","cik":1130598,"company_name":"Traws Pharma, Inc.","ticker":"TRAW","form_type":"8-K","filed_at":"2026-01-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Traws Pharma completes ratutrelvir Phase 2 enrollment; tivoxavir influenza prophylaxis study set for June 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Ratutrelvir study fully enrolled (90 pts); shows fewer AEs, no viral rebound, faster symptom resolution vs PAXLOVID.","Separate arm for PAXLOVID-ineligible patients addresses high-risk group with few effective options.","Tivoxavir marboxil compressed tablet predicted to offer 28-day influenza protection; challenge study secured for June 2026 at hVIVO.","Ratutrelvir's profile may support future studies in reducing risk of Long COVID via early viral clearance.","CEO states advancement of antiviral portfolio provides significant value inflection points."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":23180524.518987343,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101574,"accession_number":"0001104659-26-003071","cik":1130598,"company_name":"Traws Pharma, Inc.","ticker":"TRAW","form_type":"8-K","filed_at":"2026-01-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Traws Pharma files IND for flu drug TXM; ratutrelvir beats Paxlovid on symptom resolution in interim study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IND filed with FDA for tivoxavir marboxil (TXM) for influenza; final step for BARDA stockpile consideration.","Interim Phase 2 data: ratutrelvir showed faster symptom resolution vs Paxlovid (12 vs 14 days, p<0.014).","No viral rebound in ratutrelvir arm vs one in Paxlovid; fewer adverse events (7.6% mild dyspepsia vs 30% in comparator).","Ratutrelvir showed consistent safety and efficacy in Paxlovid-ineligible patients (13 patients).","Full study enrollment expected in January 2026; 95% of 90 patients enrolled."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":23180524.518987343,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117917,"accession_number":"0001104659-25-121749","cik":1130598,"company_name":"Traws Pharma, Inc.","ticker":"TRAW","form_type":"8-K","filed_at":"2025-12-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Traws Pharma ratutrelvir shows fewer adverse events and no viral rebound in interim Phase 2 COVID-19 data vs PAXLOVID","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Interim analysis of 37 patients: 25 on ratutrelvir 600 mg once daily 10 days, 12 on PAXLOVID 5-day regimen.","No viral rebound observed in ratutrelvir arm; 1 rebound (8.3%) in PAXLOVID arm.","24% of ratutrelvir cohort were PAXLOVID-ineligible; symptom improvement consistent with broader group.","Adverse events lower: 7.6% mild dyspepsia on ratutrelvir vs 30% dysgeusia/dizziness/dyspepsia on PAXLOVID.","Final data expected January 2026; enrollment >50% of planned 90-patient study."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":23180524.518987343,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117916,"accession_number":"0001104659-25-121635","cik":1130598,"company_name":"Traws Pharma, Inc.","ticker":"TRAW","form_type":"8-K","filed_at":"2025-12-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Traws Pharma grants options and RSUs to five executives with $2.33 exercise price","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Compensation Committee approved equity grants to CEO, CFO, CSO, CMO, and COO on December 12, 2025.","CEO Iain Dukes receives 147,771 options + 36,943 RSUs; CFO Charles Parker receives 61,571 options + 15,393 RSUs.","CSO C. David Pauza receives 73,886 options + 18,471 RSUs; CMO Robert Redfield receives 65,676 options + 16,419 RSUs.","COO Nikolay Savchuk receives 65,676 options + 16,419 RSUs; all options have $2.33 strike, 10-year term, vest in 1 year.","Grants made under the Amended and Restated 2021 Incentive Compensation Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":23180524.518987343,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117915,"accession_number":"0001104659-25-116962","cik":1130598,"company_name":"Traws Pharma, Inc.","ticker":"TRAW","form_type":"8-K","filed_at":"2025-11-28T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Traws Pharma shareholders approve 1.5M share increase to incentive plan and elect directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment to 2021 Incentive Compensation Plan, increasing authorized shares by 1,500,000 and extending term to November 20, 2035.","Seven directors elected: Iain Dukes, Werner Cautreels, Trafford Clarke, John Leaman, Nikolay Savchuck, M. Teresa Shoemaker, Jack E. Stover.","Advisory vote on executive compensation approved; company will hold such votes every two years, next at 2027 annual meeting.","Ratification of KPMG as independent auditor for FY2025 approved with 3,350,178 votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":23180524.518987343,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117914,"accession_number":"0001104659-25-110829","cik":1130598,"company_name":"Traws Pharma, Inc.","ticker":"TRAW","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Traws Pharma reports Q3 net loss $4.0M; Phase 2 ratutrelvir data expected YE 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $4.0M ($0.34 diluted EPS) vs $8.5M ($1.49) in Q3 2024; R&D and G&A expenses down significantly.","Cash and equivalents $6.4M at Sept 30, 2025, down from $21.3M at Dec 31, 2024; runway into Q1 2026.","Acquired key patent from Viriom for $2.6M; intangible assets of $2.6M recorded.","Ratutrelvir Phase 2 studies dosed; topline data from both studies expected by year-end 2025.","Iain Dukes permanently appointed CEO, Charles Parker CFO confirmed Oct 6; John Leaman added to board."],"consensus_eps_estimate":null,"consensus_eps_actual":1.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":2790000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":23180524.518987343,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117913,"accession_number":"0001104659-25-100455","cik":1130598,"company_name":"Traws Pharma, Inc.","ticker":"TRAW","form_type":"8-K","filed_at":"2025-10-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Traws Pharma grants 184,492 stock options to five executive officers at $3.01 strike","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Iain Dukes: 64,839 options; CFO Parker, CSO Pauza, CMO Redfield each 32,406; COO Savchuk 22,435.","Exercise price $3.01/share (Oct 10 closing); 10-year term; full vest on first anniversary (Oct 12, 2026).","Granted under Amended and Restated 2021 Incentive Compensation Plan; subject to continued service."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":23180524.518987343,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117912,"accession_number":"0001104659-25-098994","cik":1130598,"company_name":"Traws Pharma, Inc.","ticker":"TRAW","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Traws Pharma doses first subject in Phase 2 COVID study of ratutrelvir; top-line data by year-end 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First subject dosed in Phase 2 study of ratutrelvir, a ritonavir-free anti-viral for newly diagnosed COVID.","Two trials: non-inferiority versus PAXLOVID and a single-arm study for PAXLOVID-ineligible patients.","Top-line results from both Phase 2 studies expected by year-end 2025.","Ratutrelvir is once-daily, single tablet for 10 days; aims to reduce rebound and Long COVID risk."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":23180524.518987343,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117911,"accession_number":"0001104659-25-096920","cik":1130598,"company_name":"Traws Pharma, Inc.","ticker":"TRAW","form_type":"8-K","filed_at":"2025-10-06T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Traws Pharma appoints John Leaman as independent director, formalizes CEO and CFO titles","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John Leaman, MD appointed independent director effective Oct 1, 2025; joins Audit Committee.","Interim titles removed: Iain Dukes now CEO, Charles Parker now CFO of Traws Pharma.","Dr. Leaman brings experience as CFO of Cellarity, Impel Pharma, Selecta Biosciences.","Company progressing Phase 2 studies for lead candidate ratutrelvir (COVID-19 treatment).","CFO Charles Parker compensated via Stout at $500/hr, up to $50k/month for services."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":23180524.518987343,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134380,"accession_number":"0001104659-25-089564","cik":1130598,"company_name":"Traws Pharma, Inc.","ticker":"TRAW","form_type":"8-K","filed_at":"2025-09-12T23:59:59+00:00","items":["1.01","2.01","9.01"],"status":"ready","headline":"Traws Pharma acquires antiviral compound assets from Viriom for $2.35M cash","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired IP and assets for pyrrolidine antiviral compound from Viriom for $2,350,000 cash paid on September 9, 2025.","Nikolay Savchuk, Traws COO, is Executive Chairman of Viriom; Dr. Robert Redfield, Traws CMO, on Viriom board; related-party transaction approved by audit committee.","Assets include patents, license agreements, regulatory filings, and materials exclusively related to the compound and program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":23180524.518987343,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134379,"accession_number":"0001104659-25-079454","cik":1130598,"company_name":"Traws Pharma, Inc.","ticker":"TRAW","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Traws Pharma gets HREC approval for Phase 2 COVID trials of ratutrelvir; top-line data expected year-end 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First Phase 2 non-inferiority trial compares ratutrelvir 600 mg QD for 10 days vs PAXLOVID 5-day regimen in newly diagnosed COVID subjects.","Second single-arm trial tests ratutrelvir in PAXLOVID-ineligible patients; both trials expect top-line results by year-end 2025.","Ratutrelvir is ritonavir-free, once-daily for 10 days, aiming to reduce clinical rebound and Long COVID risk.","Pfizer reported $427M PAXLOVID sales in Q2 2025 (+70% YoY), highlighting continued market need for COVID treatments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":23180524.518987343,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134378,"accession_number":"0001104659-25-078060","cik":1130598,"company_name":"Traws Pharma, Inc.","ticker":"TRAW","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Traws Pharma Q2 net loss narrows to $0.9M; cash drops to $13.1M; Phase 2 COVID study planned","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $0.9M ($0.11/share) vs. $123.1M loss in Q2 2024 which included $117.5M acquisition charge.","Revenue $2.7M (vs. $57K) from deferred revenue on mutual termination of an oncology license.","Cash, cash equivalents and investments $13.1M as of June 30, down from $21.3M at Dec 31, 2024.","Phase 2 ratutrelvir (COVID) study submitted to HREC in Australia; results expected by year-end 2025.","Bird flu Phase 2 study deferred; BARDA stockpile discussions continue; Charles Parker named Interim CFO."],"consensus_eps_estimate":null,"consensus_eps_actual":1.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":2790000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":23180524.518987343,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134377,"accession_number":"0001104659-25-065842","cik":1130598,"company_name":"Traws Pharma, Inc.","ticker":"TRAW","form_type":"8-K","filed_at":"2025-07-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Traws Pharma appoints Charles Parker as Interim CFO, effective July 5, 2025, replacing Nora Brennan","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Nora Brennan resigns as Interim CFO effective July 5, 2025; no severance, will provide transition services as independent contractor through July 18.","Board appoints Charles Parker as Interim CFO effective July 5; he is a Director at Stout, a global advisory firm.","Parker has over two decades of biopharma finance experience, including $700M+ capital raises and multi-million dollar debt restructurings.","Compensation terms for Parker not yet finalized; disclosure expected when consulting agreement is completed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":23180524.518987343,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151192,"accession_number":"0001104659-25-063793","cik":1130598,"company_name":"Traws Pharma, Inc.","ticker":"TRAW","form_type":"8-K","filed_at":"2025-06-30T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Traws Pharma submits Phase 2 protocols for bird flu and COVID drugs; requests FDA meeting","summary_kind":"llm","event_type":"regulatory","confidence":"medium","bullets":["Submitted HREC Phase 2 protocol for tivoxavir marboxil (TXM) to treat H5N1 bird flu and seasonal influenza.","Submitted Type D FDA meeting request to discuss accelerated approval for TXM under the Animal Rule.","Submitted HREC Phase 2 protocol for ratutrelvir in acute COVID, including PAXLOVID-ineligible patients, with rebound and Long COVID assessments.","Cash and equivalents of $15.9M as of March 31, 2025, expected to fund operations into Q1 2026.","Continuing discussions with BARDA regarding strategic stockpile inclusion for TXM."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":23180524.518987343,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151191,"accession_number":"0001104659-25-055709","cik":1130598,"company_name":"Traws Pharma, Inc.","ticker":"TRAW","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Traws Pharma reports 80% ORR, 50% CR for rigosertib in RDEB-SCC Phase 2 study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Rigosertib Phase 2 ISS in RDEB-SCC showed 80% overall response rate (ORR) with 50% complete responses (CR) in evaluable patients.","Results published on June 3, 2025; study enrolled patients who failed prior immune checkpoint inhibitor therapy.","Company also posted corporate presentations for rigosertib and narazaciclib; narazaciclib trials are on hold pending funding.","Traws seeking partnership opportunities for rigosertib in RDEB-SCC, a high unmet need with no approved treatments.","Clinical safety database for rigosertib includes >1,300 patients across prior cancer studies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":23180524.518987343,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151190,"accession_number":"0001104659-25-052729","cik":1130598,"company_name":"Traws Pharma, Inc.","ticker":"TRAW","form_type":"8-K","filed_at":"2025-05-27T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Traws Pharma gets FDA guidance on bird flu drug tivoxavir; details stockpiling plans; cash $15.9M","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received FDA guidance on path forward for tivoxavir marboxil (TXM) for bird flu and seasonal flu; pursuing Animal Rule for accelerated approval.","Preclinical data: single oral dose of TXM protected against lethal H5N1 (dairy-worker strain) in mice, ferrets, and non-human primates.","Phase 1 data: single 480 mg dose maintained plasma levels above EC90 for ~3 weeks; no treatment-related adverse events.","US strategic stockpile estimated at 300-600 million doses; company discussing TXM inclusion with BARDA.","Cash and equivalents of $15.9M as of March 31, 2025; expected runway into Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":23180524.518987343,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151189,"accession_number":"0001104659-25-050242","cik":1130598,"company_name":"Traws Pharma, Inc.","ticker":"TRAW","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Traws Pharma corporate deck touts bird flu TXM data, COVID plans, $15.9M cash","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["TXM bird flu: 100% survival in mice, dose-dependent survival in ferrets; single dose maintained plasma >EC90 for ~3 weeks in Phase 1.","Pursuing FDA Animal Rule for bird flu; FDA meeting granted, briefing package submitted April 24, 2025.","COVID candidate ratutrelvir: ritonavir-independent 10-day regimen; briefing document planned for June 2025.","Cash $15.9M as of March 31, 2025, expected to fund operations into Q1 2026.","Legacy oncology assets (rigosertib, narazaciclib) remain; pursuing business development exit strategies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":23180524.518987343,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151188,"accession_number":"0001104659-25-048915","cik":1130598,"company_name":"Traws Pharma, Inc.","ticker":"TRAW","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Traws Pharma Q1 net income $21.5M on warrant gain; cash $15.9M; CEO transition","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of $21.5M ($2.17 basic EPS) driven by $26.5M gain from warrant liability fair value change; revenue $57K.","Cash and equivalents $15.9M as of Mar 31, 2025, down from $21.3M; runway into Q1 2026.","Submitted FDA briefing package for tivoxavir marboxil (TXM) under Animal Rule; ratutrelvir briefing package planned Q2 2025.","Iain Dukes named Interim CEO after retirement of Werner Cautreels; Jack Stover appointed Chairman.","R&D expense $2.5M (+$0.6M YoY) on virology program; G&A $2.8M (-$0.6M YoY) on lower consulting fees."],"consensus_eps_estimate":null,"consensus_eps_actual":2.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":57000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":23180524.518987343,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151187,"accession_number":"0001104659-25-036366","cik":1130598,"company_name":"Traws Pharma, Inc.","ticker":"TRAW","form_type":"8-K","filed_at":"2025-04-18T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Traws Pharma finalizes interim CEO Iain Dukes' employment; Jack Stover named Chairman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Employment agreement with Iain Dukes effective April 1, 2025: base salary $610K, target bonus 50% of base.","Term of one year, auto-renew; severance only after first anniversary unless change in control.","Dr. Dukes stepped down as Chairman on April 15, 2025; director Jack Stover appointed Chairman.","Dr. Dukes remains a board member after transitioning chairman role.","Agreement replaces April 2024 offer letter; details in Exhibit 10.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":23180524.518987343,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151186,"accession_number":"0001104659-25-032684","cik":1130598,"company_name":"Traws Pharma, Inc.","ticker":"TRAW","form_type":"8-K","filed_at":"2025-04-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Traws Pharma launches $7.4M ATM offering under existing shelf registration","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["May sell up to $7,427,749 of common stock through Citizens JMP Securities as agent/principal.","Offering under effective Form S-3 (No. 333-273081) and prospectus supplements dated March 10 and April 7, 2025.","Shares sold subject to 'baby shelf' limitation under General Instruction I.B.6. of Form S-3.","Legal opinion of Snell & Wilmer L.L.P. filed as Exhibit 5.1 to the 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":23180524.518987343,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170088,"accession_number":"0001104659-25-029687","cik":1130598,"company_name":"Traws Pharma, Inc.","ticker":"TRAW","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Traws Pharma reports FY2024 net loss of $166.5M; CEO Werner Cautreels retiring, Iain D. Dukes Interim CEO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $166.5M ($35.21/share) for FY2024, driven by $117.5M acquired IPR&D and $24.4M warrant expense.","Cash, cash equivalents and short-term investments $21.3M as of Dec 31, 2024; cash runway into Q1 2026.","CEO Werner Cautreels retiring as of March 31, 2025; Interim CEO Iain D. Dukes appointed, continuing as Chairman.","Lead candidate tivoxavir marboxil shows positive efficacy in three animal models for H5N1 bird flu; Phase 1 complete; FDA interaction sought under Animal Rule.","R&D expense $12.8M (up $1.4M); G&A expense $12.3M (up $3.2M) for FY2024."],"consensus_eps_estimate":null,"consensus_eps_actual":2.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":57000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":23180524.518987343,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170087,"accession_number":"0001104659-25-029405","cik":1130598,"company_name":"Traws Pharma, Inc.","ticker":"TRAW","form_type":"8-K","filed_at":"2025-03-28T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"CEO Werner Cautreels retiring; Iain Dukes appointed Interim CEO effective March 31, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Werner Cautreels to retire as CEO effective upon filing 2024 10-K around March 31; remains on board and as special advisor.","Iain Dukes, Executive Chairman, appointed Interim CEO; continues as Chairman.","Cautreels receives $10,000 lump sum and $10,000/month consulting fee for one year as special advisor.","No compensation changes for Dukes yet; amendment to his offer letter expected soon.","Investor update call scheduled for March 31, 2025 at 10:00 AM ET to review pipeline progress."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":23180524.518987343,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170086,"accession_number":"0001104659-25-027545","cik":1130598,"company_name":"Traws Pharma, Inc.","ticker":"TRAW","form_type":"8-K","filed_at":"2025-03-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Traws Pharma reports positive Phase 1 data for COVID-19 drug ratutrelvir; no ritonavir needed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1 data at 600 mg/day for 10 days show trough blood levels ~13x EC50 and >EC90 for 2 days post-treatment.","Ratutrelvir suppressed 18 SARS-CoV-2 strains including nirmatrelvir-resistant and Omicron variants in lab tests.","No requirement for ritonavir boosting due to favorable metabolism, potentially reducing drug-drug interaction risks.","Excellent safety/tolerability in SAD and MAD studies at all doses tested; target Phase 2 dose defined.","Company plans FDA interactions to initiate Phase 2; investor event March 31, 2025 at 10:00 AM ET."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":23180524.518987343,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170085,"accession_number":"0001104659-25-026854","cik":1130598,"company_name":"Traws Pharma, Inc.","ticker":"TRAW","form_type":"8-K","filed_at":"2025-03-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Traws Pharma: TXM shows positive H5N1 data in non-human primates; FDA meeting planned H1 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Single-dose TXM (480 mg) reduced lung viremia below quantitation vs up to 1x10^7 in controls after H5N1 challenge.","TXM-treated NHPs maintained stable weight vs 4.2% loss in controls (p<0.004).","Consistent efficacy across NHPs, ferrets (increased survival), and mice (complete survival, undetectable viremia).","Company plans FDA meeting in H1 2025 to discuss accelerated approval under the Animal Rule.","Investor event on March 31, 2025 at 10:00 AM ET to present TXM overview and next steps."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":23180524.518987343,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170084,"accession_number":"0001104659-25-026392","cik":1130598,"company_name":"Traws Pharma, Inc.","ticker":"TRAW","form_type":"8-K","filed_at":"2025-03-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Traws Pharma tivoxavir marboxil shows 100% survival in H5N1 rodent model; Phase 1 PK positive","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["100% of TXM-treated mice survived lethal H5N1 challenge; all untreated controls died by study day 6.","Single 240 mg dose maintained plasma levels at EC90 for ~25 days; well tolerated up to 480 mg in Phase 1.","TXM exhibited sub-nanomolar EC50 against circulating 2022-2023 H5N1 strains and baloxavir-resistant viruses.","Investor call scheduled for March 31, 2025 at 10:00 AM ET to review antiviral programs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":23180524.518987343,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170083,"accession_number":"0001104659-25-022193","cik":1130598,"company_name":"Traws Pharma, Inc.","ticker":"TRAW","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Traws Pharma enters ATM equity facility for up to $50M with Citizens JMP Securities","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATM agreement allows sale of common stock up to $50M aggregate, subject to baby shelf limit of $5,514,200.","Shares sold at market prices on Nasdaq via Citizens JMP as agent; commission is 3% of gross proceeds.","Prospectus supplement dated March 10, 2025 filed under Rule 424(b); Company not obligated to sell any shares.","ATM may be terminated by Company with 5 business days' notice or by Manager at any time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":23180524.518987343,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170082,"accession_number":"0001104659-25-019446","cik":1130598,"company_name":"Traws Pharma, Inc.","ticker":"TRAW","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Traws Pharma reports positive H5N1 ferret model data for tivoxavir marboxil","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Single oral dose of tivoxavir marboxil increased survival and reduced viral burden in lungs and nasal tissues in ferrets.","Data consistent with December 2024 murine model results; non-human primate study expected Q1 2025.","Company plans to approach FDA for accelerated approval under the Animal Rule after primate data.","Virtual investor update on bird flu program scheduled for March 31, 2025.","CEO Werner Cautreels and former CDC director Robert Redfield comment on urgency of bird flu threat."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":23180524.518987343,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170081,"accession_number":"0001104659-25-018636","cik":1130598,"company_name":"Traws Pharma, Inc.","ticker":"TRAW","form_type":"8-K","filed_at":"2025-02-28T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Traws Pharma regains Nasdaq compliance with $2.5M equity rule; under monitoring until Feb 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq confirmation on Feb 25, 2025 of compliance with minimum $2.5M stockholders' equity requirement.","Subject to mandatory panel monitoring through Feb 25, 2026; future non-compliance may lead to delisting without cure period.","Closed $20M gross proceeds offering on Dec 30, 2024 to strengthen financial position.","CEO cites potential transformational year ahead with bird flu/influenza antiviral pipeline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":23180524.518987343,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170080,"accession_number":"0001104659-25-015182","cik":1130598,"company_name":"Traws Pharma, Inc.","ticker":"TRAW","form_type":"8-K","filed_at":"2025-02-19T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Traws Pharma amends Series A warrant terms for certain holders","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Increases change-of-control threshold from 50% to >50% in Fundamental Transaction definition.","Revises expected volatility rate for Black Scholes Value calculation in warrant valuation.","Removes Section 3(h) which adjusted exercise price on reverse stock split events.","Series A Warrants originally issued Dec 29, 2024 as part of Class A and Class B Units."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":23180524.518987343,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170079,"accession_number":"0001104659-25-014840","cik":1130598,"company_name":"Traws Pharma, Inc.","ticker":"TRAW","form_type":"8-K","filed_at":"2025-02-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Traws Pharma stockholders approve warrant-related share issuances from Dec 2024 private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposal 1 to issue >19.99% of shares upon Pre-Funded & Series A Warrants passed: 2,369,987 for, 24,205 against.","Proposal 2 to issue shares to insiders upon warrant exercise approved: 2,370,124 for, 24,039 against.","Quorum of 65.6% (2,396,188 shares) present; adjournment proposal not used as both prior proposals passed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":23180524.518987343,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170078,"accession_number":"0001104659-25-014748","cik":1130598,"company_name":"Traws Pharma, Inc.","ticker":"TRAW","form_type":"8-K","filed_at":"2025-02-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Traws Pharma raises ~$20M in Dec 31 offering; believes it now meets Nasdaq equity minimum","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed Dec 31, 2024 unit offering; gross proceeds ~$20M, up to $52.6M more on warrant exercise.","Company now believes stockholders' equity is at least $2.5M, addressing Nasdaq Rule 5550(b)(1).","Awaiting Nasdaq confirmation; no assurance that compliance will be formally determined.","Hearing panel had granted exception until Feb 18, 2025; filing updates status."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":23180524.518987343,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170077,"accession_number":"0001104659-25-010580","cik":1130598,"company_name":"Traws Pharma, Inc.","ticker":"TRAW","form_type":"8-K","filed_at":"2025-02-07T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Traws Pharma CFO Mark Guerin resigns; Nora Brennan named Interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mark Guerin resigned as CFO effective Feb 5, 2025; receives $250K in 9 monthly installments plus $150K lump sum.","Guerin gets $75K RSUs vesting over 2 years, accelerated vesting of all outstanding awards, option exercise extended to Feb 2026.","Nora Brennan appointed Interim CFO effective Feb 5; compensation $42K/month through July 5, 2025.","Brennan previously CFO at Spectrum Pharmaceuticals and TELA Bio; led TELA Bio through IPO.","If extended after July 5, Brennan eligible for $425K salary, 115K RSUs, and target bonus up to 50% of salary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":23180524.518987343,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170076,"accession_number":"0001104659-25-005455","cik":1130598,"company_name":"Traws Pharma, Inc.","ticker":"TRAW","form_type":"8-K","filed_at":"2025-01-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Traws Pharma completes Phase 1 studies for single-dose bird flu drug tivoxavir marboxil","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1 trial showed safety, tolerability, and PK supporting dosing for H5N1 treatment and prevention.","No significant treatment-related adverse events reported across four dose levels in healthy volunteers.","Preclinical data showed potent inhibition of drug-resistant and highly pathogenic bird flu viruses.","Company plans to use data to guide upcoming regulatory meetings for accelerated development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":23180524.518987343,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187092,"accession_number":"0001104659-24-132925","cik":1130598,"company_name":"Traws Pharma, Inc.","ticker":"TRAW","form_type":"8-K","filed_at":"2024-12-31T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Traws Pharma raises up to $72.6M; initial $20M tranche to fund Bird Flu drug","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initial $20M gross proceeds from common stock and pre-funded warrants; net proceeds ~$17.9M.","Up to $52.6M additional from Series A Warrants exercisable after key Bird Flu data readouts (Ferret, NHP, Phase 2a).","Institutional investors: Perceptive Advisors, OrbiMed, Alyeska, Torrey Pines, Ikarian Capital.","Proceeds to accelerate Tivoxavir Marboxil development; cash runway extended into 1H26 (initial) and 3+ years if warrants exercised.","Closing on Dec 31, 2024; Series A Warrants subject to stockholder approval and 9.99% ownership limitation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":23180524.518987343,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187091,"accession_number":"0001104659-24-130901","cik":1130598,"company_name":"Traws Pharma, Inc.","ticker":"TRAW","form_type":"8-K","filed_at":"2024-12-20T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Luba Greenwood resigns from Traws Pharma board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Luba Greenwood resigned as director of Traws Pharma on December 16, 2024.","Resignation was voluntary and not due to any disagreement with the company.","No replacement has been announced at this time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":23180524.518987343,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187090,"accession_number":"0001104659-24-122149","cik":1130598,"company_name":"Traws Pharma, Inc.","ticker":"TRAW","form_type":"8-K","filed_at":"2024-11-22T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Traws Pharma receives Nasdaq delisting notice for equity-rule non-compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Staff notified Company on Nov 20, 2024 of non-compliance with $2.5M stockholders' equity requirement (Listing Rule 5550(b)(1)).","Company self-reported equity shortfall and requested Nov 14 hearing solely on equity rule; bid-price compliance was regained on Oct 29.","Awaiting determination from Nasdaq Hearings Panel; delisting remains a risk if plan not accepted.","Previously disclosed bid-price non-compliance resolved by 10 consecutive closing bids above $1.00/share."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":23180524.518987343,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187089,"accession_number":"0001104659-24-119064","cik":1130598,"company_name":"Traws Pharma, Inc.","ticker":"TRAW","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Traws Pharma Q3 net loss $8.5M; cash $5.4M; Phase 2 starts for COVID and flu drugs in 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $8.5M ($8.81 per share) vs $4.7M loss in Q3 2023; R&D expense $5.1M, G&A $3.5M.","Cash and short-term investments $5.4M as of Sept 30, down from $20.8M at Dec 31, 2023.","Ratutrelvir (COVID) Phase 1 data supports once-daily dosing without ritonavir; Phase 2 targeted in 2025.","Tivoxavir marboxil (flu) Phase 1 data supports single-dose treatment; Phase 2 targeted in 2025.","Luba Greenwood appointed to board of directors; shares outstanding 3,025,554 after 25:1 reverse split."],"consensus_eps_estimate":-6.2475,"consensus_eps_actual":-130.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":170000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":23180524.518987343,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187088,"accession_number":"0001104659-24-113548","cik":1130598,"company_name":"Traws Pharma, Inc.","ticker":"TRAW","form_type":"8-K","filed_at":"2024-11-01T23:59:59+00:00","items":["5.07","8.01"],"status":"ready","headline":"Traws Pharma regains bid price compliance but remains at risk of delisting due to equity deficit","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Regained compliance with Nasdaq minimum bid price requirement as of Oct 29, 2024 after 10 consecutive business days above $1.00.","Company does not believe it satisfies Nasdaq stockholders' equity minimum of $2.5M; reported deficit of ~$(105.5)M as of June 30, 2024.","Will present a plan to regain equity compliance at a Nasdaq hearing scheduled for November 14, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":23180524.518987343,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203616,"accession_number":"0001104659-24-103773","cik":1130598,"company_name":"Traws Pharma, Inc.","ticker":"TRAW","form_type":"8-K","filed_at":"2024-09-27T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Traws Pharma receives Nasdaq delisting notice; will request hearing to regain compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received delisting determination from Nasdaq on Sept 24, 2024 for failing to maintain minimum $1 bid price.","Second compliance period ended Sept 23, 2024; company did not regain compliance despite extension.","Company intends to request a hearing before Nasdaq Hearings Panel by Oct 1, 2024 to stay delisting.","Stock currently trades above $1, but no assurance of regaining compliance or meeting other listing criteria."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":23180524.518987343,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203615,"accession_number":"0001104659-24-100709","cik":1130598,"company_name":"Traws Pharma, Inc.","ticker":"TRAW","form_type":"8-K","filed_at":"2024-09-17T23:59:59+00:00","items":["5.02","5.03","5.07","5.08","8.01","9.01"],"status":"ready","headline":"Traws Pharma approves 1-for-25 reverse stock split, regains Nasdaq equity compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Board approved 1-for-25 reverse split; effective Sept 20, trading split-adjusted Sept 23.","Authorized shares increased from 125M to 250M; stockholders approved conversion of Series C Preferred.","Director James Marino resigned; Luba Greenwood appointed to board and committees.","Company believes it now satisfies Nasdaq $2.5M stockholders' equity requirement after conversion; delisting risk remains.","Annual meeting set for Oct 31, 2024; shareholder proposals due Sept 26, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":23180524.518987343,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203614,"accession_number":"0001104659-24-092496","cik":1130598,"company_name":"Traws Pharma, Inc.","ticker":"TRAW","form_type":"8-K","filed_at":"2024-08-23T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Traws Pharma receives Nasdaq delisting notice for stockholders' deficit of $105.5M","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on Aug 21, 2024 for non-compliance with minimum $2.5M stockholders' equity.","Reported stockholders' deficit of $105.5M as of June 30, 2024, below the required minimum.","Must submit a compliance plan by Oct 7, 2024; extension possible to Feb 18, 2025.","No immediate effect on listing, but failure to regain compliance may lead to delisting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":23180524.518987343,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203613,"accession_number":"0001104659-24-089914","cik":1130598,"company_name":"Traws Pharma, Inc.","ticker":"TRAW","form_type":"8-K","filed_at":"2024-08-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Traws Pharma reports Q2 net loss of $123.1M; $16.9M cash; pipeline milestones ahead","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $123.1M ($4.87 per share) includes $117.5M non-cash charge from acquired in-process R&D.","Cash, cash equivalents and short-term investments of $16.9M as of June 30, 2024; adequate through year-end.","Merger with Trawsfynydd completed April 2024; concurrent $14M private placement from Orbimed and Torrey Pines.","Tivoxavir marboxil (influenza) Phase 1 dose extension underway; topline results expected Q4 2024.","Ratutrelvir (COVID-19) completed Phase 1 SAD/MAD; Phase 2 initiation planned Q4 2024/Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":113000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":23180524.518987343,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203612,"accession_number":"0001104659-24-081155","cik":1130598,"company_name":"Traws Pharma, Inc.","ticker":"TRAW","form_type":"8-K","filed_at":"2024-07-19T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Traws Pharma appoints KPMG as new independent auditor, replacing Ernst & Young","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On July 16, 2024, Traws Pharma's Audit Committee engaged KPMG as its new independent registered public accounting firm for the year ending December 31, 2024.","During the fiscal years 2022 and 2023 and interim period through July 16, 2024, the company did not consult KPMG on accounting principles or any disagreements/reportable events.","Ernst & Young provided a letter to the SEC dated July 19, 2024, agreeing with the company's statements regarding the auditor change."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":23180524.518987343,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220122,"accession_number":"0001104659-24-076343","cik":1130598,"company_name":"Traws Pharma, Inc.","ticker":"TRAW","form_type":"8-K","filed_at":"2024-06-28T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Traws Pharma reduces stockholder meeting quorum to one-third of outstanding shares","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board adopted bylaw amendment lowering quorum from majority to one-third of outstanding common stock.","Previous quorum required a majority of issued and outstanding shares.","Amendment effective June 26, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":23180524.518987343,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2024-06-28T23:59:59+00:00|220122"}